Eosinophilic Asthma
Available biologics show similar effectiveness, safety for treating eosinophilic asthma
The biologics mepolizumab, dupilumab and benralizumab showed minimal differences in efficacy and safety in treating eosinophilic asthma, according to a review of eight studies published in The Journal of Allergy and Clinical Immunology.
Benralizumab outperforms mepolizumab in IgE reduction for severe eosinophilic asthma
Benralizumab reduced levels of IgE circulating in the blood among patients with severe eosinophilic asthma but mepolizumab did not, according to a study published in Clinical and Translational Allergy.
Benralizumab shows real-world efficacy for severe asthma regardless of nasal polyps
Benralizumab appeared effective for severe eosinophilic asthma in a real-world study of patients with and without chronic rhinosinusitis with nasal polyps, according to data published in The Journal of Allergy and Clinical Immunology.
Mepolizumab discontinuation increases asthma exacerbations, blood eosinophil count
Continued mepolizumab treatment yielded sustained clinical benefit in most patients with severe eosinophilic asthma, according to data scheduled for presentation at the American Thoracic Society International Conference.
Benralizumab auto-injector pen receives FDA approval for severe asthma
AstraZeneca announced it has received FDA approval for the self-administration of benralizumab in a prefilled, single-use auto-injector pen for patients with severe eosinophilic asthma, according to a company press release.